Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Bradley

Orthopaedic Surgery Wakefield, RI Medical Doctor

NPI 1083668883 CMS profile 185245

1 High St, Wakefield, RI 02879

Open in the dashboard

General payments

$1,361,606

607 records reported · program years 2019–2025

Research payments

$74,975

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$352,899

3 holdings reported · through program year 2025

Research they led as principal investigator

$101,982 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Michael Bradley of Wakefield, RI is reported in the CMS Open Payments database as having received $1,361,606 across 607 general payments and $74,975 in research payments paid to them. Separately, studies naming them as principal investigator received $101,982 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $352,899 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

15 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $220,315 105
2025 Research $16,800 1
2024 General $98,682 49
2024 Research $11,000 1
2023 General $194,675 100
2023 Research $6,200 1
2022 General $174,125 86
2022 Research $17,900 1
2021 General $182,286 88
2020 General $179,793 52
2020 Research $10,975 3
2019 General $311,730 127
2019 Research $12,100 3
2025 Ownership $188,993 2
2024 Ownership $163,906 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Bradley
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Michael Bradley were reported at $220,315. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Michael Bradley Orthopaedic Surgery median Middle half National median
2019 $311,730 $644 $140–$2,844 $163
2020 $179,793 $312 $75–$1,860 $114
2021 $182,286 $520 $117–$2,495 $132
2022 $174,125 $598 $128–$2,731 $149
2023 $194,675 $461 $128–$2,264 $160
2024 $98,682 $497 $134–$2,475 $164
2025 $220,315 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $860,191 356 payments
  2. FX Shoulder USA, Inc $182,704 20 payments
  3. Corin USA $97,828 45 payments
  4. OMNIlife science, Inc $79,850 112 payments
  5. Encore Medical, LP $59,256 32 payments
  6. Intellijoint Surgical Inc. $59,104 7 payments
  7. Naviswiss, Inc. $21,105 10 payments
  8. Kairos Surgical Inc $848 5 payments
  9. Stryker Corporation $269 4 payments
  10. Bioventus LLC $128 4 payments
  11. Other $323 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $583,416 55 payments
  2. Consulting Fee $371,409 100 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $295,039 27 payments
  4. Travel and Lodging $84,400 180 payments
  5. Honoraria $16,000 2 payments
  6. Food and Beverage $11,228 242 payments
  7. Gift $114 1 payment
Products named General payments · program years 2019–2025
  1. ARTHREX Arthroplasty - Implants - Total Knee Arthroplasty - Total Knee $193,748 12 payments
  2. ARTHREX Arthroplasty - Implants - Total Knee Arthroplasty - Total Knee $175,304 11 payments
  3. ARTHREX Arthroplasty - Implants - Total Knee Arthroplasty - Total Knee $148,419 9 payments
  4. ARTHREX Arthroplasty - Implants - Total Knee Arthroplasty - Total Knee $138,417 9 payments
  5. ARTHREX Arthroplasty - Implants - Partial Knee Arthroplasty - Patello Femoral $106,532 6 payments
  6. ARTHROPLASTY INSTRUMENTS KNEE ARTHROPLASTY PATELLO FEMORAL $102,870 4 payments
  7. ARTHROPLASTY INSTRUMENTS KNEE ARTHROPLASTY TOTAL KNEE $102,870 4 payments
  8. ARTHROPLASTY IMPLANTS KNEE ARTHROPLASTY TOTAL KNEE $102,870 4 payments
  9. ARTHROPLASTY IMPLANTS KNEE ARTHROPLASTY PATELLO FEMORAL $102,870 4 payments
  10. ARTHREX Arthroplasty - Implants - Total Knee Arthroplasty - Total Knee $84,531 5 payments
  11. Other $1,007,522 245 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. FX Shoulder USA, Inc $74,975 10 payments

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,227

Median for Orthopedic Surgery: 203

Drug cost

$6,805

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 318 $2,213
Diclofenac Sodium Generic 54 $1,401
Meloxicam Generic 358 $968
Tranexamic Acid Generic 163 $810
Ibuprofen Generic 36 $455
Gabapentin Generic 67 $367
Naproxen Generic 18 $225
Omeprazole Generic 158 $163
Mupirocin Generic 22 $137
Cyclobenzaprine Hcl Generic 11 $37

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$213,294

Of which drugs: $1,351

Medicare patients

318

Average age 75

Services billed

2,208

198 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 26%
Depression 26%
Osteoporosis 23%
Ischemic heart disease 22%
Chronic kidney disease 18%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 73 472 $354
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 71 454 $39

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

617 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record